Magnetite nanostructures functionalized with cytostatic drugs exhibit great anti-tumoral properties without application of high amplitude alternating magnetic fields

Romanian Journal of Morphology and Embryology

Volumn 55, Issue 2, 2014, Pages 357-362

  Voicu, Georgeta ^a   Cricǎ, Livia Elena ^a   Fufǎ, Oana ^a   Moraru, Lavinia Iuliana ^a   Popescu, Roxana Cristina ^a   Purcel, Gabriela ^a   Stoilescu, Miruna Codruţa ^a   Grumezescu, Alexandru Mihai ^a   Bleotu, Coralia ^b   Holban, Alina Maria ^a,c   Andronescu, Ecaterina ^a  

^a UNIVERSITY POLITEHNICA OF BUCHAREST   (Romania)

^b STEFAN S NICOLAU INSTITUTE OF VIROLOGY   (Romania)

^c UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

Antitumorals; Epirubicin; Fludarabine; Magnetite; Nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; MAGNETITE NANOPARTICLE;

CHEMISTRY; DRUG SCREENING; HUMAN; MAGNETIC FIELD; PARTICLE SIZE; SYNTHESIS; TUMOR CELL CULTURE; X RAY DIFFRACTION;

ANTINEOPLASTIC AGENTS; CYTOSTATIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; MAGNETIC FIELDS; MAGNETITE NANOPARTICLES; PARTICLE SIZE; TUMOR CELLS, CULTURED; X-RAY DIFFRACTION;

EID: 84903191010     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. An B, Liang Q, Zhao D, Removal of arsenic(V) from spent ion exchange brine using a new class of starch-bridged magnetite nanoparticles, Water Res, 2011, 45(5):1961-1972.
2. Taratula O, Dani RK, Schumann C, Xu H, Wang A, Song H, Dhagat P, Taratula O, Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells, Int J Pharm, 2013, 458(1):169-180.
3. Filippousi M, Papadimitriou SA, Bikiaris DN, Pavlidou E, Angelakeris M, Zamboulis D, Tian H, Van Tendeloo G, Novel core-shell magnetic nanoparticles for Taxol encapsulation in biodegradable and biocompatible block copolymers: preparation, characterization and release properties, Int J Pharm, 2013, 448(1):221-230.
4. Faria MR, Cruz MM, Gonçalves MC, Carvalho A, Feio G, Martins MBF, Synthesis and characterization of magnetoliposomes for MRI contrast enhancement, Int J Pharm, 2013, 446(1-2):183-190.
5. Ladj R, Bitar A, Eissa MM, Fessi H, Mugnier Y, Le Dantec R, Elaissari A, Polymer encapsulation of inorganic nanoparticles for biomedical applications, Int J Pharm, 2013, 458(1):230-241.
6. Gupta AK, Gupta M, Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications, Biomaterials, 2005, 26(18):3995-4021.
7. Jiang DS, Long SY, Huang J, Xiao HY, Zhou JY, Immobilization of Pycnoporus sanguineus laccase on magnetic chitosan microspheres, Biochem Eng J, 2005, 25(1):15-23.
8. Dai T, Yang E, Sun Y, Zhang L, Zhang L, Shen N, Li S, Liu L, Xie Y, Wu S, Gao Z, Preparation and drug release mechanism of CTS-TAX-NP-MSCs drug delivery system, Int J Pharm, 2013, 456(1):186-194.
9. Lee ES, Lim C, Song HT, Yun JM, Lee KS, Lee BJ, Youn YS, Oh YT, Oh KT, A nanosized delivery system of superparamagnetic iron oxide for tumor MR imaging, Int J Pharm, 2012, 439(1-2):342-348.
10. Al-Kattan A, Girod-Fullana S, Charvillat C, Ternet-Fontebasso H, Dufour P, Dexpert-Ghys J, Santran V, Bordère J, Pipy B, Bernad J, Drouet C, Biomimetic nanocrystalline apatites: emerging perspectives in cancer diagnosis and treatment, Int J Pharm, 2012, 423(1):26-36.
11. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F, Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating, Biomaterials, 2003, 24(6):1001-1011.
12. Yang PF, Lee CK, Hyaluronic acid interaction with chitosanconjugated magnetite particles and its purification, Biochem Eng J, 2007, 33(3):284-289.
13. Chertok B, Moffat BA, David AE, Yu F, Bergemann C, Ross BD, Yang VC, Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors, Biomaterials, 2008, 29(4):487-496.
14. Bomatí-Miguel O, Morales MP, Tartaj P, Ruiz-Cabello J, Bonville P, Santos M, Zhao XQ, Veintemillas-Verdaguer S, Fe-based nanoparticulate metallic alloys as contrast agents for magnetic resonance imaging, Biomaterials, 2005, 26(28): 5695-5703.
15. Lacava LM, Lacava ZGM, Da Silva MF, Silva O, Chaves SB, Azevedo RB, Pelegrini F, Gansau C, Buske N, Sabolovic D, Morais PC, Magnetic resonance of a dextran-coated magnetic fluid intravenously administered in mice, Biophys J, 2001, 80(5):2483-2486.
16. Kim DK, Mikhaylova M, Wang FH, Kehr J, Bjelke B, Zhang Y, Tsakalakos T, Muhammed M, Starch-coated superparamagnetic nanoparticles as MR contrast agents, Chem Mater, 2003, 15(23):4343-4351.
17. Hiergeist R, Andrä W, Buske N, Hergt R, Hilger I, Richter U, Kaiser W, Application of magnetite ferrofluids for hyperthermia, J Magn Magn Mater, 1999, 201(1-3):420-422.
18. Astalan AP, Ahrentorp F, Johansson C, Larsson K, Krozer A, Biomolecular reactions studied using changes in Brownian rotation dynamics of magnetic particles, Biosens Bioelectron, 2004, 19(8):945-951.
19. Mihaiescu DE, Horja M, Gheorghe I, Ficai A, Grumezescu AM, Bleotu C, Chifiriuc CM, Water soluble magnetite nanoparticles for antimicrobial drugs delivery, Lett Appl NanoBioScience, 2012, 1(2):45-49.
20. Grumezescu AM, Vasile BS, Holban AM, Eugenol functionalized magnetite nanostructures used in anti-infectious therapy, Lett Appl NanoBioScience, 2013, 2(4):120-123.
21. Grumezescu AM, Chifiriuc MC, Saviuc C, Grumezescu V, Hristu R, Mihaiescu DE, Stanciu GA, Andronescu E, Hybrid nanomaterial for stabilizing the antibiofilm activity of Eugenia carryophyllata essential oil, IEEE Trans NanoBioScience, 2012, 11(4):360-365.
22. Grumezescu AM, Essential oils and nanotechnology for combating microbial biofilms, Curr Org Chem, 2013, 17(2): 90-96.
23. Li TJ, Huang CC, Ruan PW, Chuang KY, Huang KJ, Shieh DB, Yeh CS, In vivo anti-cancer efficacy of magnetite nanocrystal-based system using locoregional hyperthermia combined with 5-fluorouracil chemotherapy, Biomaterials, 2013, 34(32):7873-7883.
24. Amarjargal A, Tijing LD, Park CH, Im IT, Kim CS, Controlled assembly of superparamagnetic iron oxide nanoparticles on electrospun PU nanofibrous membrane: a novel heatgenerating substrate for magnetic hyperthermia application, Eur Polym J, 2013, 49(12):3796-3805.
25. Wang Y, Ibrahim NL, Jiang J, Gao S, Erathodiyil N, Ying JY, Construction of block copolymers for the coordinated delivery of doxorubicin and magnetite nanocubes, J Control Release, 2013, 169(3):211-219.
26. Sadhukha T, Wiedmann TS, Panyam J, Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy, Biomaterials, 2013, 34(21):5163-5171.
27. Shen JM, Gao FY, Yin T, Zhang HX, Ma M, Yang YJ, Yue F, cRGD-functionalized polymeric magnetic nanoparticles as a dual-drug delivery system for safe targeted cancer therapy, Pharmacol Res, 2013, 70(1):102-115.
28. Bedzhova Z, Yordanov G, Preparation of epirubicin-loaded poly(butyl cyanoacrylate) colloidal particles by polymerization in a mixed organic-aqueous solvent system, Colloids Surf A Physicochem Eng Asp, 2013, 431:27-33.
29. Yordanov G, Evangelatov A, Skrobanska R, Epirubicin loaded to pre-polymerized poly(butyl cyanoacrylate) nanoparticles: preparation and in vitro evaluation in human lung adenocarcinoma cells, Colloids Surf B Biointerfaces, 2013, 107:115-123.
30. Yordanov G, Skrobanska R, Evangelatov A, Entrapment of epirubicin in poly(butyl cyanoacrylate) colloidal nanospheres by nanoprecipitation: formulation development and in vitro studies on cancer cell lines, Colloids Surf B Biointerfaces, 2012, 92:98-105.
31. Voicu G, Andronescu E, Grumezescu AM, Huang KS, Ficai A, Yang CH, Bleotu C, Chifiriuc MC, Antitumor activity of magnetite nanoparticles: influence of hydrocarbonated chain of saturated aliphatic monocarboxylic acids, Curr Org Chem, 2013, 17(8):831-840.
32. Men Y, Wang XX, Li RJ, Zhang Y, Tian W, Yao HJ, Ju RJ, Ying X, Zhou J, Li N, Zhang L, Yu Y, Lu WL, The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals, Int J Nanomedicine, 2011, 6:3125-3137.
33. Lo YL, Wang W, Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro, Chem Biol Interact, 2013, 205(3):188-197.
34. Zhang Y, Hu H, Song L, Cai L, Wei R, Jin W, Epirubicinmediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation, Toxicol Lett, 2013, 222(1):1-9.
35. Jalalian SH, Taghdisi SM, Shahidi Hamedani N, Kalat SA, Lavaee P, Zandkarimi M, Ghows N, Jaafari MR, Naghibi S, Danesh NM, Ramezani M, Abnous K, Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo, Eur J Pharm Sci, 2013, 50(2):191-197.
36. Lukenbill J, Kalaycio M, Fludarabine: a review of the clear benefits and potential harms, Leuk Res, 2013, 37(9):986-994.
37. Kohli E, Han HY, Zeman AD, Vinogradov SV, Formulations of biodegradable Nanogel carriers with 5'-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity, J Control Release, 2007, 121(1-2): 19-27.
38. Lin Y, Wei Y, Sun Y, Wang J, Synthesis and magnetic characterization of magnetite obtained by monowavelength visible light irradiation, Mater Res Bull, 2012, 47(3):614-618.
39. Voicu G, Grumezescu V, Andronescu E, Grumezescu AM, Ficai A, Ficai D, Ghitulica CD, Gheorghe I, Chifiriuc MC, Caprolactam-silica network, a strong potentiator of the antimicrobial activity of kanamycin against Gram-positive and Gram-negative bacterial strains, Int J Pharm, 2013, 446(1-2): 63-69.
40. Qian Z, Zhang Z, Chen Y, A novel preparation of surfacemodified paramagnetic magnetite/polystyrene nanocomposite microspheres by radiation-induced miniemulsion polymerization, J Colloid Interface Sci, 2008, 327(2):354-361.
41. Rummel MJ, Käfer G, Pfreundschuh M, Jäger E, Reinhardt U, Mitrou PS, Hoelzer D, Bergmann L, Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study, Ann Oncol, 1999, 10(2):183-188.
42. Bocchia M, Bigazzi C, Marconcini S, Forconi F, Marotta G, Algeri R, Lauria F, Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas, Haematologica, 1999, 84(8):716-720.
43. Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle K, Cordes HJ, Bergmann L, Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia, Eur J Haematol, 2011, 87(5):426-433.
44. Alexis F, Pridgen EM, Langer R, Farokhzad OC, Nanoparticle technologies for cancer therapy, Handb Exp Pharmacol, 2010, 197:55-86.